Canaccord Genuity Group Issues Pessimistic Forecast for Progyny (NASDAQ:PGNY) Stock Price

Progyny (NASDAQ:PGNY) had its target price lowered by research analysts at Canaccord Genuity Group from $26.00 to $19.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “hold” rating on the stock. Canaccord Genuity Group’s price objective points to a potential upside of 8.57% from the stock’s previous close.

PGNY has been the topic of several other reports. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 target price on shares of Progyny in a report on Friday, March 6th. JPMorgan Chase & Co. set a $35.00 price target on shares of Progyny in a research report on Wednesday, January 21st. KeyCorp decreased their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating on the stock in a report on Monday, March 2nd. Wall Street Zen upgraded Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Barclays initiated coverage on Progyny in a research note on Monday, December 8th. They set an “overweight” rating and a $29.00 target price for the company. Nine investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $28.45.

Progyny Stock Down 0.1%

Shares of PGNY opened at $17.50 on Wednesday. Progyny has a 52-week low of $16.75 and a 52-week high of $28.75. The stock has a fifty day simple moving average of $22.46 and a two-hundred day simple moving average of $22.78. The company has a market capitalization of $1.43 billion, a PE ratio of 26.92, a price-to-earnings-growth ratio of 1.17 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings data on Thursday, February 26th. The company reported $0.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Progyny had a net margin of 4.54% and a return on equity of 11.37%. The firm had revenue of $318.40 million during the quarter, compared to analyst estimates of $314.26 million. During the same quarter in the prior year, the firm posted $0.42 earnings per share. Progyny’s quarterly revenue was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. As a group, equities analysts anticipate that Progyny will post 0.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Progyny

In other news, EVP Allison Swartz sold 4,657 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total value of $81,031.80. Following the sale, the executive vice president directly owned 89,879 shares in the company, valued at approximately $1,563,894.60. This trade represents a 4.93% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 7,455 shares of company stock worth $129,515 over the last 90 days. 9.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Progyny

Institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd acquired a new position in shares of Progyny during the 4th quarter worth about $25,000. Federated Hermes Inc. increased its position in Progyny by 147.3% during the 3rd quarter. Federated Hermes Inc. now owns 1,375 shares of the company’s stock worth $30,000 after purchasing an additional 819 shares during the period. Hantz Financial Services Inc. raised its position in Progyny by 79.4% in the fourth quarter. Hantz Financial Services Inc. now owns 1,676 shares of the company’s stock worth $43,000 after acquiring an additional 742 shares in the last quarter. Versant Capital Management Inc increased its holdings in shares of Progyny by 61.8% in the 3rd quarter. Versant Capital Management Inc now owns 2,340 shares of the company’s stock valued at $50,000 after purchasing an additional 894 shares in the last quarter. Finally, Covestor Ltd lifted its position in shares of Progyny by 164.9% during the 3rd quarter. Covestor Ltd now owns 2,609 shares of the company’s stock valued at $56,000 after acquiring an additional 1,624 shares during the period. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.